A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 114 participants.

Also called NCT02584660

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 114 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02584660
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02584660. Randomized; no masking; primary purpose treatment. Start 2015-10-15 (actual); primary completion 2017-03-22 (actual). Results posted on 2018-04-20.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department
Acronym
MERCURY PE
Intervention (Drug)
Rivaroxaban
Intervention (Drug)
Standard-of-care
Lead sponsor
Janssen Scientific Affairs, LLC (class: industry)
Collaborator
Bayer (class: industry)

Record details

Record id
cardio:ct-nct02584660
Content hash
4f645c75572699b776d466ba9529a5cebe70730199c4df7a9091bd55ec5789da